[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.166.74.94. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Comment & Response
February 24, 2015

Alternative Pricing Strategies for Cancer Drugs

Author Affiliations
  • 1Health Technology Assessment Unit, Regional Health Service, Firenze, Italy
  • 2Italian Society of Clinical Pharmacy and Therapeutics, Milan, Italy
  • 3Italian Medicines Agency, Rome, Italy
JAMA. 2015;313(8):857. doi:10.1001/jama.2014.17814

To the Editor Dr Bach,1 in discussing indication-specific pricing for cancer drugs, examined the practical aspects of linking the price of a drug to its benefits. However, he did not mention the Italian experience in this area, which extends more than 5 years2,3 and involves a total of 162 agents, most of which are oncological drugs.

First Page Preview View Large
First page PDF preview
First page PDF preview
×